Company intelligence / Profile preview

ORA

Seattle/North Bend, Washington, United Statesoraclinical.com ↗

Ownership: Public · ORA
Development stage: Commercial

Overview

Ora Biomedical uses its proprietary WormBot-AI platform to identify small molecules that extend lifespan and improve healthspan in live animal models. The company has demonstrated proof-of-concept by restoring mobility and extending healthspan in C. elegans Alzheimer’s disease models. No clinical-stage results have been reported yet.

Therapeutic areas: OtherNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

testosterone 0.03% ophthalmic solution

Partnerships

Not publicly disclosed.

Financials

Market cap: $6.6B
Total revenue: $258.8M
Enterprise value: $9.5B

Beyond the preview

Go deeper on ORA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORA.

Explore the full profile